Neurology® Podcast

Dr. Greg Cooper talks with Dr. David G. Coughlin about the role of αSyn-SAAs in diagnosing dementia with Lewy bodies and their relationship with Alzheimer disease biomarkers. 
Read the related article in Neurology®. 
Disclosures can be found at Neurology.org.

Dr. Tesha Monteith talks with Dr. Andrew D. Hershey about the advancements in the treatment of pediatric migraines. 
Read the related article in The New England Journal of Medicine. 
Disclosures can be found at Neurology.org.

In this special episode, Dr. Roy Strowd talks with Drs. Jeff Ratliff, Tesha Monteith, and Justin Abbatemarco about non-traditional educational formats and how they're reshaping neurology training. 
Disclosures can be found at Neurology.org.

Dr. Andy Southerland talks with Dr. Dipika Aggarwal as she shares her profound journey as both a physician and a patient. After battling stage four colon cancer, she faced a stroke that changed her life. 
Disclosures can be found at Neurology.org.

The February 2026 recall features four previously posted episodes on multiple sclerosis. The episode begins with a conversation with Dr. Wallace J. Brownle discussing whether dissemination in time is essential to diagnois relapsing MS. The discussion continues with Dr. Daniel Ontaneda regarding the 2024 revisions of the McDonald criteria for diagnosing multiple sclerosis. The episode then transitions into a conversation with Dr. Jiwon Oh about BTK inhibitors and recent data on tolebrutinib in multiple sclerosis. The episode concludes with Dr. Sandra Vukusic addressing the differences in disease-modifying therapies for female versus male patients with multiple sclerosis. 
Podcast link:
Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing MS
2024 McDonald Criteria 
BTK Inhibitors in Multiple Sclerosis Treatment
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis
Podcast article:
Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis 
Diagnosis of Multiple Sclerosis: 2024 Revisions of the McDonald Criteria 
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis 
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis 
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis
Disclosures can be found at Neurology.org.